Printable versionSend by emailPDF version
June 28, 2016

In today’s ever changing Tax landscape, the recent BEPS initiative has raised many questions about the availability of strategic planning opportunities for the exploitation of intellectual property (“IP”) in foreign markets. 

A&M’s Marc Alms and Kieran Taylor, together with William Fry’s Cliona Donnelly recently discussed the impact of BEPS on IP planning in the pharmaceuticals industry. This article, first published in Bloomberg BNA, outlines how not only is such strategic planning a viable method of establishing or growing a group’s foreign operations, but that IP planning can still be effective in managing a group’s effective tax rate.


READ THE FULL ARTICLE:
Has BEPS Signaled the Death Knell for U.S. Pharmaceutical IP Migration to Ireland?